ReviewCureus2025
The Role of DNA Methylation in Insulin Resistance and Metabolic Dysregulation in Polycystic Ovary Syndrome Patients: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Polyendocrine Metabolic Ovarian Syndrome (PMOS; Formerly Polycystic Ovary Syndrome/PCOS) and Susceptibility to Microbial Infections: Mechanisms, Clinical Management, and Reproductive Consequences - A Comprehensive Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Natural Products in the Metabolic and Endocrine Modulation of Polycystic Ovary Syndrome: Current Perspectives.Nutrients · 2026Review
- The Effects ofFood science & nutrition · 2025Article
- Insulin Resistance in Polycystic Ovary Syndrome: Mechanistic Insights and Therapeutic Perspectives Independent of Obesity.Gynecology and minimally invasive therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder characterized by hyperandrogenism, ovulatory dysfunction, and metabolic disturbances, with insulin resistance (IR) playing a critical role in its pathogenesis. Emerging evidence suggests that epigenetic mechanisms, such as DNA methylation, may influence insulin signaling and metabolic pathways in PCOS by altering gene expression without changing the DNA sequence. This systematic review aims to evaluate the impact of DNA methylation on IR and metabolic dysfunction among PCOS patients by analyzing key genes involved in these processes. A comprehensive literature search was conducted using the databases Ovid, EMBASE, and Web of Science to analyze studies published between 2010 and 2025. Studies that evaluated DNA methylation and its association with IR and metabolic parameters in PCOS patients were included. Eligibility criteria followed the PRISMA guidelines. A total of 10 studies met the inclusion criteria. Hypermethylation of insulin receptor (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.